Stephen Pace, MD
Internal Medicine · Jonesboro, ARNPI 1487141420
Payments from drug & device makers
Across 283 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$768
- Amgen$632
- GSK$430
- Astellas Pharma US Inc$420
- Pfizer$356
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$253
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,79698%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $768 |
| Amgen | 47 | $632 |
| GSK | 26 | $430 |
| Astellas Pharma US Inc | 18 | $420 |
| Pfizer | 23 | $356 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $253 |
| Otsuka America Pharmaceutical, Inc. | 9 | $229 |
| AbbVie | 12 | $214 |
| Sumitomo Pharma America, Inc. | 13 | $207 |
| Boehringer Ingelheim | 11 | $205 |
| Lilly USA, LLC | 9 | $143 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Novo Nordisk | 5 | $77 |
| Novartis | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 7 | $71 |
| Bayer | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Merck | 4 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Lundbeck LLC | 3 | $48 |
| Viatris Specialty LLC | 2 | $47 |
| Exact Sciences | 3 | $45 |
| Averitas Pharma Inc. | 2 | $39 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Vertex | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Mylan Specialty L.p. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Cvrx, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Corium, LLC | 2 | $19 |
| Medtronic | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$4,896 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $56,482 |
| JardianceEmpagliflozin | 46 | $38,849 |
| OzempicSemaglutide | 44 | $38,783 |
| MounjaroTirzepatide | 21 | $22,064 |
| MyrbetriqMirabegron | 26 | $19,077 |
| TrulicityDulaglutide | 14 | $13,946 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $12,273 |
| FarxigaDapagliflozin Propanediol | 17 | $9,000 |
| GemtesaVibegron | 14 | $8,632 |
| Repatha SureclickEvolocumab | 12 | $6,627 |
| BelsomraSuvorexant | 13 | $5,465 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $4,684 |
| Doxepin Hcl | 34 | $4,535 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,474 |
| Pantoprazole Sodium | 160 | $3,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $356 | $56,48288 claims |
| Boehringer IngelheimJardiance | $205 | $38,84946 claims |
| Novo NordiskOzempic | $77 | $38,78344 claims |
| Lilly USA, LLCMounjaro, Trulicity | $143 | $36,01035 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $768 | $21,27333 claims |
| Astellas Pharma US IncMyrbetriq | $420 | $19,07726 claims |
| GSKIncruse Ellipta, Breo Ellipta | $430 | $9,15827 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $207 | $8,63214 claims |
| MerckBelsomra | $53 | $5,46513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Jonesboro
- David PyleJonesboro$93K
- John NorwoodJonesboro$22K
- Revel PorterJonesboro$12K
- Ricky TateJonesboro$11K
- Brannon TreeceJonesboro$9K
- Veryl HodgesJonesboro$8K
- Corey DiamondJonesboro$8K
- Veronica EastonJonesboro$5K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.